PATENT CLAIM ANALYSIS

Application Number: 16183309
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-05
Patent Classification: ["514", "326000"]

Abstract:
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a triazole-methyl-piperidinyl-pyrolyl-propenone structure which function as modulators of shared epitope (SE)—calreticulin (CRT) binding and/or interaction, and their use as therapeutics for the treatment of immunoregulatory abnormalities (e.g., autoimmune diseases, inflammatory diseases (e.g., chronic inflammatory disease), and bone erosive diseases) by selectively inhibiting SE-CRT interactions and/or signal transduction pathways commonly overactive or dysregulated in arthritic and/or other diseases or conditions.

Claim (Index 16):
The method of  claim 15 , wherein the disease or condition is one or more of rheumatoid arthritis, a bone destroying arthritic condition, periodontal disease, osteoporosis, osteomyelitis, bone metastasis, bone fracture healing.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 98.0
- Lexical Diversity: 1.44776
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14441758', '15819758', '14795123', '16013607', '14122611']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7619849057498379
- 35 USC 102 Novelty (BERT): 0.5279146541579566
- Combined Prediction Score: 0.7385778805906498
- Mean Citation Score: 277.062044
- Max Citation Score: 279.62033
- Similarity Product: 159.493952791664

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test